Medigene to participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
16. August 2023 14:30 ET
|
Medigene AG
Planegg/Martinsried, August 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for...
Medigene AG to report Second Quarter and Six Months 2023 Financial Results and Corporate Update on August 17, 2023
10. August 2023 11:30 ET
|
Medigene AG
Planegg/Martinsried, August 10, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies
22. Juni 2023 12:10 ET
|
Medigene AG
Planegg/Martinsried, 22 June 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene to Present Data Highlighting the Enhanced Tumor Cell Killing Effects of Adding the PD1-41BB Switch Receptor to Multiple TCR-T Therapies at the Immuno-Oncology Summit Europe
14. Juni 2023 09:00 ET
|
Medigene AG
Planegg/Martinsried, June 14, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for...
Medigene to Host Virtual R&D Event on TCR-T Therapies for Solid Tumors
13. Juni 2023 08:00 ET
|
Medigene AG
Planegg/Martinsried, June 13, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs
01. Juni 2023 07:00 ET
|
Medigene AG
Medigene is building a broad KRAS library consisting of multiple T cell receptors (TCRs) targeting multiple KRAS mutations and multiple HLAs, covering large patient populations suffering from...
Medigene AG to participate at BIO International in Boston
30. Mai 2023 10:30 ET
|
Medigene AG
Planegg/Martinsried, May 30, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene AG Expands Patent Portfolio for its End-to-End Platform
22. Mai 2023 09:00 ET
|
Medigene AG
Planegg/Martinsried, May 22, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene AG to present at upcoming investor conferences
08. Mai 2023 06:30 ET
|
Medigene AG
Planegg/Martinsried, May 8, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Expitope 3.0 presented at CIMT enables more comprehensive analysis of target antigens and increases accuracy of safety assessment
04. Mai 2023 06:00 ET
|
Medigene AG
Planegg/Martinsried, May 4, 2023, Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...